Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Conditioning Following AlloHCT

Comparing myeloablative to reduced-intensity conditioning

Publish date:: November 11, 2015

Myeloablative conditioning (MAC), but not reduced-intensity conditioning (RIC), overcomes the negative effect of pretransplant flow-cytometric evidence of leukemia (FC+) following allogeneic hematopoietic cell transplant (alloHCT). This according to a study of 203 patients with acute myeloid leukemia (AML), including 130 allografts with umbilical cord blood (UCB) and 73 sibling donors. Researchers found:

• Twenty-five patients were FC+, including 18.7% receiving MAC and 8.1% receiving RIC alloHCT.

• Among patients receiving RIC, FC+ was associated with significantly inferior relapse (HR=3.8), disease-free survival (HR=2.9), and overall survival (HR=3.4).

• In contrast, FC+ status was not associated with relapse or decreased overall survival after MAC.

Citation: Ustun C, Courville E, DeFor T, et al. Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in AML. [Published online ahead of print November 6, 2015]. Biol Blood Marrow Trans. doi: 10.1016/j.bbmt.2015.10.024.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,